<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Anzai M</submitter><funding>MEXT | Japan Society for the Promotion of Science</funding><funding>MEXT | Japan Science and Technology Agency (JST)</funding><funding>MEXT | Japan Society for the Promotion of Science (JSPS)</funding><funding>University of Tokyo</funding><funding>MEXT | Japan Science and Technology Agency</funding><pagination>643</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12015293</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>8(1)</volume><pubmed_abstract>Bone-destructive diseases are caused by dysregulated osteoclastogenesis. Osteoclast differentiation is positively regulated by the ligand for receptor activator of nuclear factor kappa B (RANKL) binding to the RANK on progenitor cells. RANK then forms a multivalent interaction with an adapter molecule, tumor necrosis factor receptor-associated factor 6 (TRAF6), to transduce various downstream signals. We used affinity-based screening of a multivalent random-peptide library to identify a tetravalent peptide, WHD-tet, that binds to the RANK-binding region of TRAF6 through a multivalent interaction. CR4-WHD-tet, a cell-permeable form of WHD-tet, efficiently inhibited the RANKL-induced differentiation of bone-marrow cells to osteoclasts and osteoclastogenesis in a mouse model. CR4-WHD-tet specifically inhibited the recruitment of MAPK kinase 3 to TRAF6 without affecting other signal transducers in a late stage of differentiation, inhibiting the activation of p38-MAPK, which promotes the final stage. Thus, the interaction modulator CR4-WHD-tet fine-tunes the formation of a critical signaling complex to inhibit osteoclastogenesis.</pubmed_abstract><journal>Communications biology</journal><pubmed_title>Clustered peptide regulating the multivalent interaction between RANK and TRAF6 inhibits osteoclastogenesis by fine-tuning signals.</pubmed_title><pmcid>PMC12015293</pmcid><funding_grant_id>JPMJSP2129</funding_grant_id><funding_grant_id>JP22J11001</funding_grant_id><pubmed_authors>Kawabata H</pubmed_authors><pubmed_authors>Waku T</pubmed_authors><pubmed_authors>Ikegami A</pubmed_authors><pubmed_authors>Inoue JI</pubmed_authors><pubmed_authors>Anzai M</pubmed_authors><pubmed_authors>Watanabe-Takahashi M</pubmed_authors><pubmed_authors>Okuda Y</pubmed_authors><pubmed_authors>Sakurai H</pubmed_authors><pubmed_authors>Nishikawa K</pubmed_authors><pubmed_authors>Masuda Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Clustered peptide regulating the multivalent interaction between RANK and TRAF6 inhibits osteoclastogenesis by fine-tuning signals.</name><description>Bone-destructive diseases are caused by dysregulated osteoclastogenesis. Osteoclast differentiation is positively regulated by the ligand for receptor activator of nuclear factor kappa B (RANKL) binding to the RANK on progenitor cells. RANK then forms a multivalent interaction with an adapter molecule, tumor necrosis factor receptor-associated factor 6 (TRAF6), to transduce various downstream signals. We used affinity-based screening of a multivalent random-peptide library to identify a tetravalent peptide, WHD-tet, that binds to the RANK-binding region of TRAF6 through a multivalent interaction. CR4-WHD-tet, a cell-permeable form of WHD-tet, efficiently inhibited the RANKL-induced differentiation of bone-marrow cells to osteoclasts and osteoclastogenesis in a mouse model. CR4-WHD-tet specifically inhibited the recruitment of MAPK kinase 3 to TRAF6 without affecting other signal transducers in a late stage of differentiation, inhibiting the activation of p38-MAPK, which promotes the final stage. Thus, the interaction modulator CR4-WHD-tet fine-tunes the formation of a critical signaling complex to inhibit osteoclastogenesis.</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Apr</publication><modification>2025-07-01T03:05:14.16Z</modification><creation>2025-07-01T03:05:14.16Z</creation></dates><accession>S-EPMC12015293</accession><cross_references><pubmed>40263556</pubmed><doi>10.1038/s42003-025-08047-2</doi></cross_references></HashMap>